Neprilysin

Neutral endopeptidase;NEP;Cluster of differentiation 10;CD10



Neprilysin (NEP) is a type II membrane metalloendopeptidase composed of 750 residues with an active site containing a zinc-binding motif (HEXXH) at the extracellular carboxyl terminal domain. Neprilysin is capable of degrading the monomeric and the oligomeric forms of Aβ peptide. Neprilysin is the dominant Aβ peptide-degrading enzyme in the brain; Neprilysin becomes inactivated and down-regulated during both the early stages of Alzheimer's disease (AD) and aging.

Neprilysin is a neutral endopeptidase and its inhibition increases bioavailability of natriuretic peptides, bradykinin, and substance P, resulting in natriuretic, vasodilatatory, and anti-proliferative effects.

Neprilysin Inhibitors & Modulators

Candoxatril
(UK 79300)

Cat. No.: HY-19649

Bioactivity: Candoxatril is a neutral endopeptidase (**NEP**) inhibitor.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



LCZ696
(Sacubitril mixture with Valsartan)

Cat. No.: HY-18204A

Bioactivity: LCZ696 is a dual **angiotensin II** receptor and **neprilysin** inhibitor.

Purity: 99.96%
Clinical Data: Launched
Size: 10mM x 1mL in Water,
5 mg, 10 mg, 50 mg



NEP-In-1

Cat. No.: HY-U00294

Bioactivity: NEP-IN-1 is a neutral endopeptidase (**NEP**) inhibitor with **IC_{50}** of 2 nM for **dNEP**.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



NEP-IN-2

Cat. No.: HY-U00336

Bioactivity: NEP-IN-2 is an inhibitor of **neutral endopeptidase**, used in the research of proliferation in atherosclerosis, restenosis.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Phosphoramidon Disodium

Cat. No.: HY-N2021A

Bioactivity: Phosphoramidon disodium is a **metalloprotease** inhibitor. Phosphoramidon inhibits endothelin-converting enzyme (**ECE**), neutral endopeptidase (**NEP**), and angiotensin-converting enzyme (**ACE**) with **IC_{50}** values of 3.5, 0.034, and 78 μM, respectively.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water,
1 mg, 5 mg, 10 mg, 25 mg, 50 mg



Racecadotril
(Acetorphan)

Cat. No.: HY-17399

Bioactivity: Racecadotril (acetorphan), a potent enkephalinase inhibitor (IC50= 4.5 uM), protects endogenous enkephalins from degradation. IC50 value: 4.5 uM Target: Enkephalinase Racecadotril is a peripherally acting enkephalinase inhibitor with an IC50 of 4.5 uM. Unlike other medications used to treat...

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
200 mg, 1 g



Sacubitril
(AHU-377)

Cat. No.: HY-15407

Bioactivity: Sacubitril (AHU-377) is a potent **NEP** inhibitor with an **IC_{50}** of 5 nM. Sacubitril (AHU-377) is a component of the heart failure medicine LCZ696.

Purity: 99.71%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Sacubitril hemicalcium salt
(AHU-377 (hemicalcium salt))

Cat. No.: HY-15407A

Bioactivity: Sacubitril hemicalcium salt (AHU-377 hemicalcium salt) is a potent **NEP** inhibitor with an **IC_{50}** of 5 nM. Sacubitril hemicalcium salt is a component of the heart failure medicine LCZ696.

Purity: 99.61%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg, 500 mg, 1 g



Sacubitrilat
(LBQ-657)

Cat. No.: HY-17620

Bioactivity: Sacubitrilat is an active **neprilysin** (**NEP**) inhibitor.

Purity: 99.85%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 25 mg, 50 mg



SQ28603
(SQ28,603; Squibb 28603)

Cat. No.: HY-U00171

Bioactivity: SQ28603 is a potent and selective inhibitor of neutral endopeptidase 3.4.24.11 (**NEP**), an enzyme that degrades atrial natriuretic peptide (ANP).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

TD-0212

Cat. No.: HY-114412

Bioactivity: TD-0212 (compound 35) is an orally active dual pharmacology **angiotensin II type 1 receptor (AT_1)** antagonist and **neprilysin (NEP)** inhibitor, with a **pK_i** of 8.9 for AT_1 and a **pIC_{50}** of 9.2 for NEP [1].

Purity: >98%

Clinical Data: No Development Reported

Size: